The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia A treatment: Is B domain-deleted FVIII equivalent to full-length FVIII?

Therapeutic Drug Monitoring

Volumn 34, Issue 1, 2012, Pages 110-117

  Johnston, Atholl ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

B domain deleted; factor VIII; full length FVIII; hemophilia A; pharmacokinetics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BIOCHEMISTRY; BIOEQUIVALENCE; BLEEDING TENDENCY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MONITORING; DRUG POTENCY; HEMOPHILIA A; HEMOSTASIS; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE DRUG DOSE;

BIOLOGICAL AVAILABILITY; COAGULANTS; DNA, RECOMBINANT; DRUG MONITORING; FACTOR VIII; HEMOPHILIA A; HUMANS; PEPTIDE FRAGMENTS; THERAPEUTIC EQUIVALENCY;

EID: 84856092868     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318244fa5a     Document Type: Article

References (48)

1. Soucie MJ, Richardson LC, Evatt BL, et al. For the hemophilia surveillance system project investigators. Risk factors for infection with HBVand HCV in a large cohort of hemophiliac males. Transfusion. 2002; 41:338-343. (Pubitemid 32238531)
2. Jewell NP. Quantifying the source of infection for HIV-infected haemophiliacs in the U.K. from 1979 to 1984. Stat Med. 2009;28: 1464-1472.
3. Toole JT, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihemophilic factor. Nature. 1984;312:342-347. (Pubitemid 15209311)
4. Khrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis. 2006;17: 379-388. (Pubitemid 43941580)
5. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512. (Pubitemid 16053817)
6. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia. 2009;15:1187-1196.
7. Jankowski MA, Patel H, Rouse JC, et al. Defining full-length recombinant factor VIII: A comparative structural analysis. Haemophilia. 2007;13:30-37. (Pubitemid 46002342)
8. Toole JJ, Pittman DD, Orr EC, et al. A large region (;95kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A. 1986;83:5939-5942. (Pubitemid 16000629)
9. Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81:2925-2935. (Pubitemid 23162110)
10. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Sem Hematol. 2001;38(suppl 4):44-51. (Pubitemid 32612098)
11. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Sem Hematol. 2001;38(suppl 4):52-59. (Pubitemid 32618681)
12. Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38-49. (Pubitemid 36511631)
13. Hanna WT, Zimmerman CE. Lack of adequate bleed prevention and FVIII activity recovery with Refacto®: A series of case studies in haemophilia A patients. Blood. 2001;98. Abstract 2222.
14. Keeling D. Switching between full-length and B-domain deleted factor VIII and the risk of inhibitors. Haemophilia. 2006;12:690-691. (Pubitemid 44697546)
15. Roussel-Robert V, Torchet MF, Legrand F, et al. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four haemophilia A previously treated patients. J Thromb Haemost. 2003;1:2450-2451.
16. Aledort LM, Navicks RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-Analysis of prospective clinical studies. J Thromb Haemost. 2011;9:2180-2129.
17. Gruppo RA, Brown D, Wilkes MM, et al. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis-A metaanalysis. Haemophilia. 2003;9:251-260. (Pubitemid 36622025)
18. Lee ML, Morfini M. Controversial use of meta-Analysis for factor VIII pharmacokinetic data. Haemophilia. 2003;9:746-747. (Pubitemid 37540819)
19. Van der Bom JG, Fischer K, Van den Berg HM. Meta-Analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis. Haemophilia. 2003;9:744. (Pubitemid 37540817)
20. Gruppo RA, Brown D, Wilkes MM, et al. Meta-Analysis of observational studies of full-length and B-domain-deleted factor FVIII for prophylaxis-A standard statistical approach. Haemophilia. 2003;9:748-50. (Pubitemid 37540820)
21. Gruppo RA, Brown D, Wilkes MM, et al. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII-A robust meta-Analytic finding. Haemophilia. 2004;10:449-451. (Pubitemid 39317752)
22. Mickaelson M. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis-Another rebuttal. Haemophilia. 2003; 10:305-307.
23. Gruppo RA, Brown D, Wilkes MM, et al. Meta-Analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII. Haemophilia. 2004;10:747-750. (Pubitemid 40028595)
24. Hubbard AR, Sands D, Sandberg E, et al. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost. 2003;90: 1088-1093. (Pubitemid 38004428)
25. Epstein JD, Li-McLeod JM. Retrospective analysis of factor VIII utilization in matched haemophilia A patients treated with either fulllength or B domain-deleted recombinant factor VIII. Poster presented at: 22nd Congress of the International Society on Thrombosis and Haemostasis (ISTH); July 16, 2009; Boston, MA.
26. Epstein J, Xiong Y, Woo P, et al. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients [Published online ahead of print July, 2011]. Haemophilia. 2011;1-6. doi:10.1111/ j.1365-2516.2011.02636.x.
27. Collins PW, Fischer K, Morfini M, et al. Björkman S on behalf of international prophylaxis study group (IPSG) pharmacokinetics expert working group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2-10.
28. CHMP (2010). Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr **). Available at: Www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/ WC500070039.pdf (accessed December 28, 2011).
29. FDA. Code of Federal Regulations Title 21. Volume 5, revised as of April 2009. US Food and Drug Administration, www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.1, accessed December 28, 2011.
30. CHMP. 2010. Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor VIII Products. Available at: Www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003614.pdf. Accessed September 6, 2010.
31. Health Canada. 2006. Guidance for Industry: Bioequivalence Requirements: Critical Dose Drugs. Available at: dhp-mps/alt-formats/pdf/prodpharma/applic- demande/guide-ld/bio/critical-dose-critique-eng.pdf. Accessed September 25, 2010.
32. DiPaola J, Smith MO, Klamroth R, et al. ReFacto® and Advate®: A single-dose, randomized, two-period cross over pharmacokinetics study in subjects with haemophilia A. Haemophilia. 2007;13:124-130. (Pubitemid 46237943)
33. Kelley BD, Tannatt M, Magnusson R, et al. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII. Biotechnol Bioeng. 2004;87:400-412. (Pubitemid 39078287)
34. Mickaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Sem Hematol. 2001;38(suppl 4):13-23. (Pubitemid 32618680)
35. Mickaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia. 1998;4:646-650. (Pubitemid 28351899)
36. Barrowcliffe TW. Factor VIII and factor IX sub-committee. Recommendations for the assay of high-purity factor VII concentrates. Thromb Haemost. 1993;70:876-877.
37. Refacto. Summary of Product Characteristics. Available at: Http://www. medicines.org.uk/emc/medicine/21767/SPC/refacto%20af%20powder%20 and%20solvent%20for%20solution%20for%20injection/, accessed December 28, 2011.
38. Refacto AF. Summary of Product Characteristics. Available at: Http:// emc.medicines.org.uk/medicine/21767.
39. Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A; demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009;15:869-880.
40. Mickaelsson M, Oswaldsson U, Frank L. Comparison of activity and antigen measurements in a pharmacokinetic study of recombinant factor VIII SQ. Haemophilia. 1998;4:187 (Abstract).
41. Morfini M, Cinotti S, Bellatreccia A, et al. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost. 2003;1:2283-2289.
42. Assessment report for ReFacto AF. International Nonproprietary Name: Moroctocog alfa. Procedure No. EMEA/H/C/II/59-68 EMA http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/ 000232/WC500049011.pdf, accessed December 28, 2011.
43. Fijnvandraat K, Berntorp E, ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (rFVIII SQ) pharmacokinetics and initial safety aspects in haemophilia A patients. Thromb Haemost. 1997;77:298-302. (Pubitemid 27084919)
44. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost. 2008;7:413-420.
45. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14:361-372.
46. X. Li X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of FVIII Bdomain on platelet binding. Biochemistry. 1997;36:10760-10767. (Pubitemid 27382566)
47. Eaton DL, Wood WI, Eaton D, et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry. 1986;25:8343-8347. (Pubitemid 17003930)
48. Meulien P, Faure T, Mischler F, et al. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Prot Engin. 1988;2:301-306. (Pubitemid 18268266)